The gut microbiome is an immunological modulator affecting therapeutic responses and efficacy of certain immunotherapy agents such as PD-1, PD-L1, and CTLA-4 inhibitors and has been shown to be associated with positive or negative outcomes from therapy [107] and may serve as a promising modifiable strategy in the treatment of cancer. Here, CTLA4 is linked to cancer.